Pharmacoepidemiological Data Analysis

The contract requires performing advanced statistical analysis using Veterans Affairs electronic health record data to assess the effects of GLP-1 receptor agonists on outcomes related to HIV and substance use disorders. The work involves comprehensive data management, including cleaning, structuring, and validating large-scale clinical datasets, followed by the application of propensity-score matching techniques to reduce selection bias and create comparable cohorts. Regression modeling will be employed to estimate causal relationships between GLP-1 agonist exposure and key health outcomes, ensuring robustness through appropriate adjustment for confounding variables and sensitivity analyses. All analyses must adhere to strict confidentiality and compliance standards given the sensitive nature of the health data. The effort is structured as a subcontract under the National Institutes of Health, NIDA, part of the Department of Health and Human Services, with performance expected to be conducted in Bethesda, Maryland. The solicitation was posted on July 22, 2026, and responses are due by July 30, 2026, with the North American Industry Classification System code 541611 indicating it falls under scientific research and development services. While the contract does not specify a set-aside category or point of contact, the focus is squarely on delivering methodologically sound pharmacoepidemiological findings that support evidence-based policy and clinical decision-making in dual-diagnosis populations.